APA (7th ed.) Citation

Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., . . . Van Biesen, W. (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology, dialysis, transplantation, 31(3), . https://doi.org/10.1093/ndt/gfv456

Chicago Style (17th ed.) Citation

Gansevoort, Ron T., et al. "Recommendations for the Use of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Position Statement on Behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice." Nephrology, Dialysis, Transplantation 31, no. 3 (2016). https://doi.org/10.1093/ndt/gfv456.

MLA (9th ed.) Citation

Gansevoort, Ron T., et al. "Recommendations for the Use of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Position Statement on Behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice." Nephrology, Dialysis, Transplantation, vol. 31, no. 3, 2016, https://doi.org/10.1093/ndt/gfv456.